SIBO - Small Intestinal Bacterial Overgrowth
  • Welcome
  • About SIBO
    • Overview
    • Symptoms
    • Associated Diseases
    • Testing
  • Treatment
    • Overview
    • Antibiotics
    • Herbal Antibiotics
    • Elemental Formula
    • Diet
    • Prevention of Relapse
  • Learning More
  • Studies
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    • 2009
    • 1990's
    • 1980's
  • Resources
    • Finding a Doctor
    • Testing
    • Handouts
    • Books
    • Cookbooks
    • Diet/Recipe Websites
    • Apps
    • Discussion Groups
    • Podcasts
    • MMC Videos
    • Elemental Diet Videos
  • Contact
    • About Dr. Siebecker
    • Skype Consultations

2015 Research Articles

Overview
  • Current views on the etiopathogenesis, clinical manifestation, diagnostics, treatment and correlation with other nosological entities of SIBO.  PMID:25657082
  • Small intestinal bacterial overgrowth syndrome in children.  PMID:25960812
  • Small Bowel Bacterial Overgrowth in Children: A Comprehensive Review.  PMID:26196206
  • SIBO: Dysbiosis Has A New Name

Causes/Risk Factors
  • Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model.  PMID: 25424202
  • Small Bowel Bacterial Overgrowth Associated with Persistence of Abdominal Symptoms in Children Treated with a Proton Pump Inhibitor.  PMID:25681195
  • Duodenal Aspirates for Small Intestine Bacterial Overgrowth: Yield, PPIs, and Outcomes after Treatment at a Tertiary Academic Medical Center. PMID:25694782
  • What are the effects of proton pump inhibitors on the small intestine?  PMID:26078557
  • Association between chronic use of proton pump inhibitors and small- intestinal bacterial overgrowth assessed using lactulose hydrogen breath tests.  PMID:25916046
  • Jejunal diverticulosis found in a patient with long-standing pneumoperitoneum and pseudo-obstruction on imaging: a case report.  PMID:26220890
  • [Prevalence of gastrointestinal disorders in adults with common variable immunodeficiency at Specialty Hospital Dr. Bernardo Sepulveda].  PMID:25758107

Associated Diseases
  • Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea.  PMID:25653855
  • The biopsy pathology of non-coeliac enteropathy.  PMID:25234408
  • Management of pediatric intestinal failure.  PMID:25752806
  • An insight into the gastrointestinal component of fibromyalgia: clinical manifestations and potential underlying mechanisms.  PMID:25119830
  • Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome.  PMID:25865706
  • Possible underestimation of SIBO in IBS patients: is lack of Glucose Breath Test standardization responsible?  PMID:26220649
  • Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.  PMID:26139425
  • Small intestinal bacterial overgrowth prevalence in celiac disease patients is similar in healthy subjects and lower in irritable bowel syndrome patients.  PMID:26070374
  • Irritable Bowel Syndrome and the Small Intestinal Microflora. What Do We Know?  PMID:26076568
  • Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in iran.  PMID:25628852
  • The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors.  PMID:25855934
  • [Small intestinal bacterial overgrowth as a cause of lactase deficiency].  PMID:25864343
  • Carbohydrate Malabsorption and Putative Carbohydrate-Specific Small Intestinal Bacterial Overgrowth: Prevalence and Diagnostic Overlap Observed in an Austrian Outpatient Center.  PMID:26138365
  • Breath hydrogen and methane are associated with intestinal symptoms in patients with chronic pancreatitis.  PMID:26278025
  • Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease.  PMID:26097546
  • Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis.  PMID:25932262
  • Small intestinal bacterial overgrowth and toll like receptor signaling in patients with nonalcoholic fatty liver disease.  PMID:26212089
  • Management of pancreatic, gastrointestinal and liver complications in adult cystic fibrosis.  PMID:26001957
  • Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response.  PMID:25990116
  • Clinical Significance of the Glucose Breath Test in Patients with Inflammatory Bowel Disease.  PMID:25612007
  • Environmental enteric dysfunction: an overview.  PMID:25902619
  • Prospective Study of Malabsorption and Malnutrition After Esophageal and Gastric Cancer Surgery.  PMID:26583669
  • Small intestinal bacterial overgrowth in patients with refractory functional gastrointestinal disorders.  PMID:26554916
  • Macronutrient intakes in obese subjects with or without small intestinal bacterial overgrowth: an alimentary survey.  PMID:26375876
  • The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease.  PMID:26374094
  • Small Intestinal Bacterial Overgrowth Diagnosed by Glucose Hydrogen Breath Test in Post-cholecystectomy Patients.  PMID:26351251
  • What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis?  PMID:26339892
  • Fecal calprotectin in systemic sclerosis and review of the literature.  PMID:25661980
Testing
  • Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.  PMID: 25970536 
  • Inclusion Of A Novel Ibs Blood Panel For Diagnosing Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D): A Uk Perspective.  PMID:26531982
  • A Novel Ibs Diagnostic Blood Panel Can Enhance A Positive Diagnostic Strategy Versus A Strategy Of Exclusion For Patients With Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D): Cost Implications For Denmark.  PMID: 26531981
  • Cost-Minimization For A Novel Ibs Diagnostic Blood Panel Versus Standard Exclusionary Diagnostic Testing For Diarrhea Predominant Irritable Bowel Syndrome: A United States Perspective.  PMID:26531980
  • Impact Of A Novel Ibs Diagnostic Blood Panel For Mexico: Cost Implications To The Mexican Private Practice For Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D).  PMID:26531979
  • Potential For Cost Savings Associated With A Novel Ibs Blood Panel For Diagnosing Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D): Italian Perspective.  PMID:26531976
  • Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test.  PMID:25600077
  • Diagnostic modalities for the evaluation of small bowel disorders. PMID:25635667 
  • Possible underestimation of SIBO in IBS patients: is lack of Glucose Breath Test standardization responsible?  PMID:26220649
  • Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients.  PMID:25914466
  • Fecal calprotectin in systemic sclerosis and review of the literature.  PMID:25661980
  • What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis?  PMID:26339892
  • Duodenal Aspirates for Small Intestine Bacterial Overgrowth: Yield, PPIs, and Outcomes after Treatment at a Tertiary Academic Medical Center.  PMID:25694782
  • Additional Value of CH₄ Measurement in a Combined (13)C/H₂ Lactose Malabsorption Breath Test: A Retrospective Analysis.  PMID:26371034
  • Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.  PMID:26362282
  • Scintigraphy Demonstrates High Rate of False-positive Results From Glucose Breath Tests for Small Bowel Bacterial Overgrowth.  PMID:26241509
  • Healthy control subjects are poorly defined in case-control studies of irritable bowel syndrome.  PMID: 25609236
  • Measurement of oro-caecal transit time by magnetic resonance imaging.  PMID: 25576231  DOI: 10.1007/s00330-014-3575-1
  • Pilot Study on Gas Patterns of Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth Following Ingestion of Lactulose.  doi: 10.4236/ojgas.2015.511025.

Treatment: Herbal Antibiotics
  • Efficacy of a Quebracho, Conker Tree, and M. balsamea Willd Blended Extract in a Randomized Study in Patients with Irritable Bowel Syndrome with Constipation (Atrantil)

Antibiotic Treatment: Rifaximin
  • Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.  PMID:25641072
  • Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.  PMID:26028929
  • Profile of rifaximin and its potential in the treatment of irritable bowel syndrome.  PMID:26089696
  • Susceptibility to rifaximin and other antimicrobial agents of bacteria isolated from acute gastrointestinal infections in Mexico.  PMID:26525276
  • Rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea.  PMID:26218792
  • Rifaximin: the revolutionary antibiotic approach for Irritable Bowel Syndrome.  PMID:26202193
  • Rifaximin: An Antibiotic with Important Biologic Effects.  PMID:26202192
  • Central and mucosal immunity are modified by non absorbable antibiotics treatment in uncomplicated diverticular disease.  PMID:26202195
  • Understanding the molecular mechanisms of rifaximin in the treatment of gastrointestinal disorders - a focus on the modulation of host tissue function.  PMID:26202186
  • Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases.  PMID:26162610
  • Rifaximin and Eluxadoline - Newly Approved Treatments for Diarrhea-Predominant Irritable Bowel Syndrome: What is Their Role in Clinical Practice Alongside Alosetron?  PMID:26559529
  • Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.  PMID:26558923

Prokinetics: Prucalopride (Resolor)
  • Management of opioid-induced constipation for people in palliative care.  PMID:26126675
  • Long term outcome of Prucalopride for chronic constipation: a single centre study.  PMID:25951504
  • New pharmacological treatment options for irritable bowel syndrome with constipation.  PMID:26548544

Microbiome
  • Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome.  PMID:25865706
  • Irritable Bowel Syndrome and the Small Intestinal Microflora. What Do We Know?  PMID:26076568
  • Differences of microbiota in small bowel and faeces between irritable bowel syndrome patients and healthy subjects.  PMID:26595305
  • No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls.  PMID: 25687743

Low FODMAP Diet
  • Role of FODMAPs in Patients With Irritable Bowel Syndrome: A Review.  PMID:25694210
  • Food Components and Irritable Bowel Syndrome.  PMID:25680668
  • Diets that differ in their FODMAP content alter the colonic luminal microenvironment.  PMID:25016597
  • Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome.  PMID: 26104013
  •   Editorial: predicting response to a low FODMAP diet in children - authors' reply.  PMID:26278562
  •   Editorial: predicting response to a low FODMAP diet in children.  PMID:26278561
  • Clinical response in Mexican patients with irritable bowel syndrome treated with a low diet low in fermentable carbohydrates (FODMAP).  PMID:26300323
  • Does a low FODMAP diet improve symptoms in Mexican patients with IBS?  PMID:26275634
  • Low FODMAP diet.  PMID:26273081
  • Diet low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial.  PMID:26255043
  • Does a low FODMAP diet help IBS?  PMID:26251411
  • Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome.  PMID:26104013
  • Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?  PMID:26078292
  • Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis.  PMID:25982757
  • [Insufficient evidence of the effect of the low FODMAP diet on irritable bowel syndrome].  PMID:25922242
  • Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome.  PMID:25903636
  • Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome.  PMID:25871564
  • The Science, Evidence, and Practice of Dietary Interventions in Irritable Bowel Syndrome.  PMID:25769411
  • Dietary treatment of irritable bowel syndrome.  PMID:25601299
  • The low-FODMAP diet for irritable bowel syndrome: Lights and shadows.  PMID:26548734


15% Off All Supplements at Fullscript
If you value this website, consider supporting the free information provided on siboinfo.com and it's newsletter, which helps SIBO sufferers world wide.
​Site author:  Dr Allison Siebecker
Powered by Create your own unique website with customizable templates.